FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation

scientific article published on 01 August 1999

FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0022-5347(05)68632-6
P8608Fatcat IDrelease_m2tkb54f4rbgphzzghrgtzpqfi
P698PubMed publication ID10411093

P2093author name stringGiri D
Ittmann M
Ropiquet F
Lamb DJ
P433issue2
P921main subjectprostatic hypertrophyQ506659
P304page(s)595-599
P577publication date1999-08-01
P1433published inJournal of UrologyQ15709979
P1476titleFGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation
P478volume162

Reverse relations

cites work (P2860)
Q37281184A signaling network in phenylephrine-induced benign prostatic hyperplasia
Q36331201Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia
Q31912970Alternative splicing of fibroblast growth factor receptors in human prostate cancer
Q33520245Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer
Q43693825Basic fibroblast growth factor and keratinocyte growth factor over-expression in benign prostatic hyperplasia
Q34057789Cultured stromal cells: an in vitro model of prostatic mesenchymal biology
Q38915711Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets
Q61798949Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia
Q28144257FGF-10 is expressed at low levels in the human prostate
Q52723926Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN.
Q28215493Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis
Q36390245Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting
Q37258877Growth factors in benign prostatic hyperplasia: basic science implications
Q35745901Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia
Q35747214Interleukin-6 is an autocrine growth factor in human prostate cancer.
Q35746575Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia
Q39914178Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model
Q39825713Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
Q38210468Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors
Q54410051Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Q38363715Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo
Q92030387Stimulation of Prostate Cells by the Senescence Phenotype of Epithelial and Stromal Cells: Implication for Benign Prostate Hyperplasia
Q35640720Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor
Q41840130The senescence-associated secretory phenotype promotes benign prostatic hyperplasia
Q89851597Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia
Q77359737Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate
Q52588865[Pathophysiology and therapy of benign prostatic hyperplasia].

Search more.